News
-
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma -
PRESS RELEASE
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Telomir-1 by Telomir Pharmaceuticals demonstrates tumor growth inhibition by 50% in prostate cancer model, suppresses cancer progression, and neutralizes chemotherapy toxicity, providing breakthrough findings -
-
-
-
-
-